Key result
Atorvastatin improves FMD and lowers LDL cholesterol versus control in moderately nicotine-dependent smokers.
Why the study?
The effect of atorvastatin on vascular endothelial function in moderately nicotine-dependent smokers was investigated due to limited data in this population.
Does atorvastatin improve vascular endothelial function in moderately nicotine-dependent smokers?
RCT (n=160)
randomly divided
Does atorvastatin improve vascular endothelial function in moderately nicotine-dependent smokers?
p-value: p=<0.05
Atorvastatin significantly improves vascular endothelial function and lipid profiles in moderately nicotine-dependent smokers over 12 months.
Atorvastatin improves endothelial function in nicotine-dependent smokers; extends RCT evidence of vascular benefits beyond lipid lowering.
We investigated the effect of atorvastatin on vascular endothelial function in moderately nicotine-dependent smokers. One hundred and sixty moderately nicotine-dependent smokers were randomly divided into the atorvastatin group (N = 80) and the control group (N = 80). Total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose levels, aspartate aminotransferase, total bilirubin, creatine phosphokinase, and brachial artery flow-mediated vasodilation function (FMD) were measured before and 12 months after atorvastatin treatment. After a 12-month atorvastatin therapy, the TC and LDL-C levels of patients were decreased significantly (P < 0.05) and the FMD of patients were improved significantly (P < 0.05). Compared with the control group, TC and LDL-C of the patients were significantly decreased (P < 0.05) and the FMD of the patients were significantly improved (P < 0.05). Atorvastatin may significantly improve endothelial function in moderately nicotine-dependent smokers.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2014) conducted an RCT in Moderately nicotine-dependent smokers (n=160). Atorvastatin vs. Control group was evaluated on Vascular endothelial function (brachial artery flow-mediated vasodilation function [FMD]) (p=<0.05). Atorvastatin significantly improved brachial artery flow-mediated vasodilation function and decreased total and LDL cholesterol compared to control in moderately nicotine-dependent smokers (P<0.05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: